

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM830735

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Intellectual Property Security Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Heron Therapeutics, Inc.		08/09/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Hercules Capital, Inc., as Agent		
Street Address:	400 Hamilton Avenue, Suite 310		
City:	Palo Alto		
State/Country:	CALIFORNIA		
Postal Code:	94301		
Entity Type:	Corporation: MARYLAND		
PROPERTY NUMBERS Total: 37			
Property Type	Number	Word Mark	
Registration Number:	2724941	A.P. PHARMA	
Registration Number:	2807409	A.P. PHARMA	
Registration Number:	7044489	APONVIE	
Registration Number:	7069700	APONVIE	
Registration Number:	7069701	APONVIE	
Registration Number:	2732851	BIOCHRONOMER	
Registration Number:	2732850	BIOCHRONOMER	
Serial Number:	97860793	BIOCHRONOMER	
Serial Number:	97860796	BIOCHRONOMER	
Registration Number:	5419060	CINVANTI	
Registration Number:	5932962	CINVANTI (APREPITANT) INJECTABLE EMULSIO	
Registration Number:	6134178	DEVELOPING BEST-IN-CLASS MEDICINE. IMPRO	
Registration Number:	6134179	DEVELOPING BEST-IN-CLASS MEDICINE. IMPRO	
Registration Number:	6814967	HERON	
Registration Number:	5515599	HERON COMMITMENT PROGRAM	
Registration Number:	5515456	HERON CONNECT	
Registration Number:	5515457	HERON CONNECT	
Registration Number:	5003789	HERON THERAPEUTICS	
Registration Number:	6660895	HERON THERAPEUTICS	

OP \$940.00 2724941

Property Type	Number	Word Mark
Registration Number:	6660896	HERON THERAPEUTICS
Registration Number:	5013325	HERON THERAPEUTICS
Registration Number:	6660897	HERON THERAPEUTICS
Registration Number:	6660898	HERON THERAPEUTICS
Registration Number:	4118925	SUSTOL
Registration Number:	5019134	SUSTOL
Registration Number:	6434813	ZYNRELEF
Registration Number:	6480562	ZYNRELEF
Registration Number:	6782150	ZYNRELEF
Registration Number:	6541124	ZYNRELEF
Registration Number:	6541127	ZYNRELEF
Registration Number:	6480561	ZYNRELEF
Registration Number:	6782149	ZYNRELEF
Registration Number:	6541125	ZYNRELEF
Registration Number:	6541126	ZYNRELEF
Registration Number:	6782089	ZYNRELEF
Registration Number:	6782147	ZYNRELEF
Registration Number:	6782148	ZYNRELEF

CORRESPONDENCE DATA

Fax Number: 2138918763

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: rhonda.deleon@lw.com

Correspondent Name: LATHAM & WATKINS LLP

Address Line 1: 355 SOUTH GRAND AVENUE

Address Line 4: LOS ANGELES, CALIFORNIA 90071-1560

ATTORNEY DOCKET NUMBER:	054809-0100
NAME OF SUBMITTER:	Rhonda DeLeon
SIGNATURE:	/RHONDA DELEON/
DATE SIGNED:	08/09/2023

Total Attachments: 30
source=Hercules - Heron - IP Security Agreement Executed#page1.tif
source=Hercules - Heron - IP Security Agreement Executed#page2.tif
source=Hercules - Heron - IP Security Agreement Executed#page3.tif
source=Hercules - Heron - IP Security Agreement Executed#page4.tif
source=Hercules - Heron - IP Security Agreement Executed#page5.tif
source=Hercules - Heron - IP Security Agreement Executed#page6.tif
source=Hercules - Heron - IP Security Agreement Executed#page7.tif
source=Hercules - Heron - IP Security Agreement Executed#page8.tif

source=Hercules - Heron - IP Security Agreement Executed#page9.tif
source=Hercules - Heron - IP Security Agreement Executed#page10.tif
source=Hercules - Heron - IP Security Agreement Executed#page11.tif
source=Hercules - Heron - IP Security Agreement Executed#page12.tif
source=Hercules - Heron - IP Security Agreement Executed#page13.tif
source=Hercules - Heron - IP Security Agreement Executed#page14.tif
source=Hercules - Heron - IP Security Agreement Executed#page15.tif
source=Hercules - Heron - IP Security Agreement Executed#page16.tif
source=Hercules - Heron - IP Security Agreement Executed#page17.tif
source=Hercules - Heron - IP Security Agreement Executed#page18.tif
source=Hercules - Heron - IP Security Agreement Executed#page19.tif
source=Hercules - Heron - IP Security Agreement Executed#page20.tif
source=Hercules - Heron - IP Security Agreement Executed#page21.tif
source=Hercules - Heron - IP Security Agreement Executed#page22.tif
source=Hercules - Heron - IP Security Agreement Executed#page23.tif
source=Hercules - Heron - IP Security Agreement Executed#page24.tif
source=Hercules - Heron - IP Security Agreement Executed#page25.tif
source=Hercules - Heron - IP Security Agreement Executed#page26.tif
source=Hercules - Heron - IP Security Agreement Executed#page27.tif
source=Hercules - Heron - IP Security Agreement Executed#page28.tif
source=Hercules - Heron - IP Security Agreement Executed#page29.tif
source=Hercules - Heron - IP Security Agreement Executed#page30.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (this "Agreement") dated as of August 9, 2023, is made by HERON THERAPEUTICS, INC., a Delaware corporation (the "Grantor"), in favor of HERCULES CAPITAL, INC., in its capacity as administrative agent and collateral agent for the Lenders (as defined below) (in such capacity, "Agent").

RECITALS

A. Grantor has entered into that certain Working Capital Facility Agreement, of even date herewith, with certain financial institutions party thereto (the "Lenders") and Agent (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Loan Agreement"). All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of all the Secured Obligations, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. Grant of Security Interest. To secure the prompt and complete payment when due of all of the Secured Obligations, Grantor grants and pledges to Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

(a) any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) all patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions, re-examination certificates, utility models, and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(f) all mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the "Mask Works");

(g) any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) all licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) all amendments, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) all proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing, the Intellectual Property Collateral does not include (a) any "intent to use" trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, provided, that upon submission and acceptance by the United States Patent and Trademark Office of an amendment to allege use of an intent-to-use trademark application pursuant to 15 U.S.C. Section 1060(a) (or any successor provision) such intent-to-use application shall constitute Collateral, and (b) nonassignable licenses or contracts, which by their terms require the consent of the licensor thereof or another party (but only to the extent such prohibition on transfer is enforceable under applicable law, including, without limitation, Sections 9406, 9407 and 9408 of the UCC) and (c) any Excluded Account.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights to record and register this Agreement upon request by Agent.

Grantor hereby authorizes Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

3. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Agent with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

4. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement by facsimile, portable document format (.pdf) or other electronic transmission will be as effective as delivery of a manually executed counterpart hereof.

5. Successors and Assigns. The provisions of this Agreement shall inure to the benefit of the parties hereto and their respective successors and assigns. Grantor shall not assign its obligations under this Agreement without Agent's express prior written consent, and any such attempted assignment shall be void and of no effect. Agent may assign, transfer, or endorse its rights hereunder pursuant to the terms of the Loan Agreement without prior notice to Grantor, and all of such rights shall inure to the benefit of Agent's successors and assigns.

6. Governing Law. This Agreement has been negotiated and delivered to Agent in the State of California, and shall have been accepted by Agent in the State of California. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

7. Electronic Execution of Certain Other Documents. The words "execution," "execute," "signed," "signature," and words of like import in or related to any document to be signed in connection with this Agreement

and the transactions contemplated hereby (including without limitation assignments, assumptions, amendments, waivers and consents) shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, the California Uniform Electronic Transactions Act, or any other similar state laws based on the Uniform Electronic Transactions Act.

[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:


HERON THERAPEUTICS, INC., a Delaware corporation



By: Ira Duarte
Title: Executive Vice President, Chief Financial Officer

AGENT:

HERCULES CAPITAL, INC., a Maryland corporation

By: 
5EPEC0D055204EB...

Name: Prentis Robinson III

Title: Associate General Counsel

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

[See attached]

Country	Title	Application No. Application Date	(Publication No.)
			Patent No. Issue Date
USA	Peg-Poly(Ortho Ester) Graft Copolymers And Pharmaceutical Compositions	11392989 2006-03-28	7456213 2008-11-25
USA	Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron	12564881 2009-09-22	8252304 2012-08-28
USA	Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron	13279938 2011-10-24	8252305 2012-08-28
USA	Process for preparing a semi-solid delivery vehicle comprising granisetron	13279949 2011-10-24	8252306 2012-08-28
USA	Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron	13552083 2012-07-18	8715710 2014-05-06
USA	Compositions of a polyorthoester and an aprotic solvent	14210263 2014-03-13	9744163 2017-08-29
USA	Compositions of a polyorthoester and an aprotic solvent	14210318 2014-03-13	9592227 2017-03-14
USA	Compositions of a polyorthoester and an aprotic solvent	14213658 2014-03-14	9446036 2016-09-20
USA	Long-acting polymeric delivery systems	14691464 2015-04-20	10213510 2019-02-26
USA	Compositions of a polyorthoester and an organic acid excipient	14691491 2015-04-20	10980886 2021-04-20
USA	Emulsion formulations of aprepitant	14859013 2015-09-18	9808465 2017-11-07
USA	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	15012532 2016-02-01	9974742 2018-05-22
USA	Emulsion formulations of aprepitant	15083071 2016-03-28	9561229 2017-02-07
USA	Long-acting polymeric delivery systems	15260820 2016-09-09	9694079 2017-07-04
USA	Compositions of a polyorthoester and an aprotic solvent	15269806 2016-09-19	9913909 2018-03-13
USA	Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron	15269856 2016-09-19	9913910 2018-03-13
USA	Long-acting polymeric delivery systems	15331759 2016-10-21	11083730 2021-08-10
USA	Long-acting polymeric delivery systems	15331767 2016-10-21	9801945 2017-10-31
USA	Emulsion formulations of aprepitant	15398928 2017-01-05	10500208 2019-12-10
USA	Compositions of a polyorthoester and an aprotic solvent	15457545 2017-03-13	10398686 2019-09-03

Country	Title	Application No. Application Date	(Publication No.) Patent No. Issue Date
USA	Long-acting polymeric delivery systems	15621782 2017-06-13	10898575 2021-01-26
USA	Long-acting polymeric delivery systems	15644715 2017-07-07	10098957 2018-10-16
USA	Long-acting polymeric delivery systems	15702697 2017-09-12	11083797 2021-08-10
USA	Emulsion formulations of aprepitant	15705201 2017-09-14	9974793 2018-05-22
USA	Emulsion formulations of aprepitant	15705208 2017-09-14	9974794 2018-05-22
USA	Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron	15897093 2018-02-14	10357570 2019-07-23
USA	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	15965638 2018-04-27	10624850 2020-04-21
USA	Long-acting polymeric delivery systems	16107965 2018-08-21	10632199 2020-04-28
USA	METHOD OF ADMINISTERING EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST	16261459 2019-01-29	(20190231688)
USA	Compositions of a polyorthoester and an aprotic solvent	16514860 2019-07-17	11253504 2022-02-22
USA	POST-SURGICAL PAIN TREATMENT	16563726 2019-09-06	(20200078363)
USA	Emulsion formulations of aprepitant	16669262 2019-10-30	10953018 2021-03-23
USA	Emulsion formulations of an NK-1 receptor antagonist and uses thereof	16820311 2020-03-16	11173118 2021-11-16
USA	Long-acting polymeric delivery systems	17129715 2020-12-21	11413350 2022-08-16
USA	METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST	17180593 2021-02-19	(20210173877)
USA	METHODS OF USE OF EMULSION FORMULATIONS OF APREPITANT	17194114 2021-03-05	(20210186981)
USA	COMPOSITIONS OF A POLYORTHOESTER AND AN ORGANIC ACID EXCIPIENT	17209078 2021-03-22	(20210205458)
USA	LONG-ACTING POLYMERIC DELIVERY SYSTEMS	17372315 2021-07-09	(20210330796)
USA	COMPOSITIONS OF A POLYORTHOESTER AND AN APROTIC SOLVENT	17572493 2022-01-10	(20220387595)

Country	Title	Application No. Application Date	(Publication No.) Patent No. Issue Date
USA	METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST	17979577 2022-11-02	(20230072781)
Australia	Compositions of a polyorthoester and an aprotic solvent	AU2014228313 A 2014-03-13	AU2014228313B2 2019-01-17
Australia	Long-acting polymeric delivery systems	AU2015249949 A 2015-04-20	AU2015249949B2 2020-07-30
Australia	Compositions Of A Polyorthoester And An Aprotic Solvent	AU2019202415 A 2019-04-08	AU2019202415B2 2020-10-01
Australia	Post-surgical pain treatment	AU2019337104 A 2019-09-06	AU2019337104A1 2021-03-25
Australia	Long-acting polymeric delivery systems	AU2020207850 A 2020-07-23	AU2020207850B2 2023-02-23
Australia	Compositions Of A Polyorthoester And An Aprotic Solvent	AU2020250230 A 2020-10-07	AU2020250230B2 2023-01-12
Australia	Long-acting polymeric delivery systems	AU2023202876 A 2023-05-09	AU2023202876A1 2023-05-25
Brazil	Composition, Semi-Solid Composition And Its Use	BR11201624665 A 2015-04-20	BR112016024665B1 2023-04-11
Brazil	Post-Surgical Pain Treatment	BR1120214331 A 2019-09-06	BR112021004331A2 2021-08-03
Canada	Compositions Of A Polyorthoester And An Aprotic Solvent	CA2906666A 2014-03-13	CA2906666C 2019-12-24
Canada	Long-Acting Polymeric Delivery Systems	CA2946281A 2015-04-20	CA2946281C 2022-12-13
Canada	Long-Acting Polymeric Delivery Systems	CA3174824A 2015-04-20	CA3174824A1 2015-10-29
Canada	Post-Surgical Pain Treatment	CA3111570A 2019-09-06	CA3111570A1 2020-03-12
China	Compositions of polyorthoesters and aprotic solvents	CN20201091059 0A 2014-03-13	CN111956598A 2020-11-20
China	Long-acting polymer delivery system	CN20211117386 0A 2015-04-20	CN113908284A 2022-01-11
China	Long-acting polymer delivery system	CN20221039064 0A 2015-04-20	CN114886899A 2022-08-12

Country	Title	Application No. Application Date	(Publication No.) Patent No. Issue Date
China	Long-acting polymer delivery system	CN20221039064 6A 2015-04-20	CN115025099A 2022-09-09
China	aprepitant emulsion preparation	CN20158005044 9A 2015-09-18	CN106852118A 2017-06-13
China	Treatment of post-operative pain	CN20198007105 8A 2019-09-06	CN112955144A 2021-06-11
Denmark	Langtidsvirkende Polymerafgivelsessystemer	DK2015718423 T 2015-04-20	DK3134068T3 2021-10-04
Denmark	Sammensætninger Af En Polyorthoester Og En Organisk Syre-Excipiens	DK2015719954 T 2015-04-20	DK3134070T3 2020-12-21
Europe	Semi-Solid Delivery Vehicle And Pharmaceutical Compositions	EP2005802951A 2005-09-27	EP1796629B1 2014-11-12
Europe	Semi-solid delivery vehicle and pharmaceutical compositions	EP2014192547A 2005-09-27	EP2902012B1 2018-08-08
Europe	Semi-Solid Delivery Vehicle And Pharmaceutical Compositions	EP2018187338A 2005-09-27	EP3424492B1 2020-05-27
Europe	Compositions Of A Polyorthoester And An Aprotic Solvent	EP2014714137A 2014-03-13	EP2968111A1 2016-01-20
Europe	Long-Acting Polymeric Delivery Systems	EP2015718423A 2015-04-20	EP3134068B1 2021-07-21
Europe	Compositions Of A Polyorthoester And An Organic Acid Excipient	EP2015719954A 2015-04-20	EP3134070B1 2020-09-23
Europe	Compositions Of A Polyorthoester And An Organic Acid Excipient	EP2020190588A 2015-04-20	EP3785700A1 2021-03-03
Europe	Long-Acting Polymeric Delivery Systems	EP2021179540A 2015-04-20	EP3936115A1 2022-01-12
Europe	Emulsion Formulations Of Aprepitant	EP2015772163A 2015-09-18	EP3193830A1 2017-07-26
Europe	A Pharmaceutical Composition Comprising A Delivery System, An Amide-Type Local Anesthetic, And Meloxicam	EP2016791743A 2016-10-21	EP3509601A1 2019-07-17
Europe	Post-Surgical Pain Treatment	EP2019783171A 2019-09-06	EP3846811A1 2021-07-14
Hong Kong	Long-Acting Polymeric Delivery Systems		HK40074984A 2023-01-13
Hong Kong	Semi-Solid Delivery Vehicle And Pharmaceutical Compositions	HK2016101403 A 2016-02-05	HK1213477B 2019-06-28
Hong Kong	Long-Acting Polymeric Delivery Systems	HK2017107934 A 2017-08-09	HK1233968B 2022-04-01

Country	Title	Application No. Application Date	(Publication No.) Patent No. Issue Date
Hong Kong	Emulsion Comprising An Nk-1 Receptor Antagonist	HK2019125057 A 2019-06-12	HK40001723A 2020-03-06
Hong Kong	Semi-Solid Delivery Vehicle And Pharmaceutical Compositions	HK2019126500 A 2019-07-09	HK40003214B 2021-01-08
Hong Kong	A Pharmaceutical Composition Comprising A Delivery System, An Amide-Type Local Anesthetic, And Meloxicam	HK20206000911 A 2020-01-03	HK40011647A 2020-07-17
Hong Kong	Compositions Of A Polyorthoester And An Aprotic Solvent	HK20214026822 A 2021-03-08	HK40036858A 2021-06-04
Hong Kong	Compositions Of A Polyorthoester And An Organic Acid Excipient	HK20214037927 A 2021-09-01	HK40048305A 2021-12-03
Hong Kong	Semi-Solid Delivery Vehicle And Pharmaceutical Compositions	HK20214044597 A 2021-12-15	HK40054578A 2022-02-25
Hong Kong	Post-Surgical Pain Treatment	HK20216045247 A 2021-12-24	HK40056343A 2022-03-25
Hong Kong	Long-Acting Polymeric Delivery Systems	HK20224055757 A 2022-06-27	HK40066724A 2022-08-26
Hong Kong	Long-Acting Polymeric Delivery Systems	HK20224056356 A 2022-07-07	HK40067456A 2022-09-09
Hong Kong	Long-Acting Polymeric Delivery Systems	HK20224063446 A 2022-11-07	HK40074055A 2022-12-30
Japan	Polyorthoester and the composition of an aprotic solvent	JP2016502182A 2014-03-13	JP06454322B2 2019-01-16
Japan	A semi-solid delivery excipient/filler and a pharmacological composition	JP2014232639A 2014-11-17	JP06057972B2 2017-01-11
Japan	Long-term acting polymer delivery system	JP2016563468A 2015-04-20	JP06702882B2 2020-06-03
Japan	The composition of polyorthoester and an organic acid additive	JP2016563469A 2015-04-20	JP06723162B2 2020-07-15
Japan	The emulsion formulation of aprepitant	JP2017514863A 2015-09-18	JP06741655B2 2020-08-19
Japan	The emulsion containing a NK-1 receptor antagonist	JP2018539883A 2016-02-01	JP06829257B2 2021-02-10
Japan	Polyortho ester and the composition of an organic acid additive	JP2019149028A 2019-08-15	JP06977003B2 2021-12-08
Japan	Emulsion Comprising Nk-1 Receptor Antagonist	JP202045436A 2020-03-16	JP2020109115A 2020-07-16




Country	Title	Application No. Application Date	(Publication No.)
			Patent No. Issue Date
Japan	Long-acting polymer delivery system	JP202081756A 2020-05-07	JP07181248B2 2022-11-30
Japan	Polyorthoester And Composition Of Aprotic Solvent	JP2020125201A 2020-07-22	JP2020169224A 2020-10-15
Japan	Delivery System, Amide Type Topical Anesthetic And Pharmaceutical Composition Including Meloxicam	JP2021101634A 2021-06-18	JP2021138773A 2021-09-16
Japan	Long-Acting Polymeric Delivery Systems	JP2021183275A 2021-11-10	JP2022017553A 2022-01-25
Japan	Compositions Of Polyorthoester And Organic Acid Excipient	JP202264460A 2022-04-08	JP2022082776A 2022-06-02
Mexico	COMPOSITIONS OF ONE POLYORTHOESTER And ONE APROTIC SOLVENT	MX201512887A 2015-09-14	MX352907B 2017-12-13
Mexico	Long-Acting Polymeric Delivery Systems.	MX201613719A 2016-10-19	MX380990B 2021-03-29
Mexico	Long-Acting Polymeric Supply Systems	MX20213558A 2016-10-19	MX2021003558A 2021-05-27
Mexico	Treatment Of Post-Surgical Pain	MX20212556A 2021-03-04	MX2021002556A 2021-06-15
Morocco	Traitement Post-Chirurgical De La Douleur	MA53553A 2019-09-06	MA53553A 2021-07-14
None.	Compositions Of A Polyorthoester And An Aprotic Solvent	KR20227006848 A 2014-03-13	KR2505642B1 2023-03-06
Portugal	Long-Acting Polymeric Delivery Systems	PT718423T 2015-04-20	PT3134068T 2021-10-18
Portugal	Compositions Of A Polyorthoester And An Organic Acid Excipient	PT719954T 2015-04-20	PT3134070T 2020-12-21
Serbia	Compositions Of A Polyorthoester And An Organic Acid Excipient	RS2020P1530A 2015-04-20	RS61202B1 2021-01-29
Serbia	Long-Acting Polymeric Delivery Systems	RS2021P1252A 2015-04-20	RS62435B1 2021-11-30
South Korea	Compositions Of A Polyorthoester And An Aprotic Solvent	KR20157029636 A 2014-03-13	KR2238495B1 2021-04-09
South Korea	Compositions Of A Polyorthoester And An Aprotic Solvent	KR20217010021 A 2014-03-13	KR2370470B1
South Korea	Long-Acting Polymeric Delivery Systems	KR20167032287 A 2015-04-20	KR2450730B1 2022-10-05
South Korea	Emulsion Formulations Of Aprepitant	KR20177008598 A 2015-09-18	KR2424837B1 2022-07-25

Country	Title	Application No. Application Date	(Publication No.) Patent No. Issue Date
South Korea	Emulsion Comprising An Nk-1 Receptor Antagonist	KR20187025071 A 2016-02-01	KR2018118136A 2018-10-30
South Korea	Pain treatment after surgery	KR20217009121 A 2019-09-06	KR2021060492A 2021-05-26
Taiwan	Semi-solid delivery vehicle and pharmaceutical compositions	TW2005133844 A 2005-09-28	TWI407966B 2013-09-11
Taiwan	Compositions of a polyorthoester and an aprotic solvent	TW2014109628 A 2014-03-14	TWI653984B 2019-03-21
Taiwan	Long-acting polymeric delivery systems	TW2015112718 A 2015-04-21	TWI675661B 2019-11-01
Taiwan	Post-surgical pain treatment	TW2019132238 A 2019-09-06	TW202023567A 2020-07-01
Turkey	Combinations of a polyorthoester and an organic acid excipient	TR202020480A 2015-04-20	TR202020480T4 2020-12-21

EXHIBIT C








Trademarks

[See attached]







Country of Registration	Mark	International Class(es)	Application No Filing Date	Registration No Registration Date
USA	A.P. PHARMA 	1, 42	76089915 13-JUL-2000	2724941 10-JUN-2003
USA	 A.P. PHARMA	1, 42	78096056 30-NOV-2001	2807409 20-JAN-2004
USA	APONVIE	5	97038308 21-SEP-2021	7044489 02-MAY-2023
USA	APONVIE	42	97056540 01-OCT-2021	7069700 30-MAY-2023
USA	APONVIE	44	97056543 01-OCT-2021	7069701 30-MAY-2023
USA	BIOCHRONOMER	1, 5	76208241 09-FEB-2001	2732851 01-JUL-2003
USA	BIOCHRONOMER	10	76208238 09-FEB-2001	2732850 01-JUL-2003
USA	BIOCHRONOMER	42	97860793 28-MAR-2023	
USA	BIOCHRONOMER	44	97860796 28-MAR-2023	
USA	CINVANTI	5	87101607 12-JUL-2016	5419060 06-MAR-2018
USA	CINVANTI (APREPITANT) INJECTABLE EMULSION 	5	87893278 25-APR-2018	5932962 10-DEC-2019
USA	DEVELOPING BEST-IN-CLASS MEDICINE. IMPROVING LIVES.	42	88595055 27-AUG-2019	6134178 25-AUG-2020
USA	DEVELOPING BEST-IN-CLASS MEDICINE. IMPROVING LIVES.	44	88595100 27-AUG-2019	6134179 25-AUG-2020
USA	HERON	5	97004444 31-AUG-2021	6814967 09-AUG-2022
USA	HERON COMMITMENT PROGRAM	35, 36	87667703 01-NOV-2017	5515599 10-JUL-2018
USA	HERON CONNECT	35	87608960 14-SEP-2017	5515456 10-JUL-2018
USA	HERON CONNECT	36	87608962 14-SEP-2017	5515457 10-JUL-2018
USA	HERON THERAPEUTICS	5	86198233 19-FEB-2014	5003789 19-JUL-2016











Country of Registration	Mark	International Class(es)	Application No Filing Date	Registration No Registration Date
USA	HERON THERAPEUTICS	42	90260219 16-OCT-2020	6660895 01-MAR-2022
USA	HERON THERAPEUTICS	44	90260224 16-OCT-2020	6660896 01-MAR-2022
USA	HERON THERAPEUTICS 	5	86198235 19-FEB-2014	5013325 02-AUG-2016
USA	HERON THERAPEUTICS 	42	90260225 16-OCT-2020	6660897 01-MAR-2022
USA	HERON THERAPEUTICS 	44	90260226 16-OCT-2020	6660898 01-MAR-2022
USA	SUSTOL	5	77765494 22-JUN-2009	4118925 27-MAR-2012
USA	SUSTOL 	5	86721014 11-AUG-2015	5019134 09-AUG-2016
USA	ZYNRELEF	5	87718146 12-DEC-2017	6434813 27-JUL-2021
USA	ZYNRELEF 	5	90173827 11-SEP-2020	6480562 07-SEP-2021
USA	ZYNRELEF 	10	90869621 06-AUG-2021	6782150 05-JUL-2022
USA	ZYNRELEF 	42	90173819 11-SEP-2020	6541124 26-OCT-2021
USA	ZYNRELEF 	44	90173828 11-SEP-2020	6541127 26-OCT-2021
USA	ZYNRELEF 	5	90173820 11-SEP-2020	6480561 07-SEP-2021
USA	ZYNRELEF 	10	90869617 06-AUG-2021	6782149 05-JUL-2022
USA	ZYNRELEF 	42	90173821 11-SEP-2020	6541125 26-OCT-2021
USA	ZYNRELEF 	44	90173824 11-SEP-2020	6541126 26-OCT-2021








Country of Registration	Mark	International Class(es)	Application No Filing Date	Registration No Registration Date
USA	ZYNRELEF	10	90845710 23-JUL-2021	6782089 05-JUL-2022
USA	ZYNRELEF	42	90869613 06-AUG-2021	6782147 05-JUL-2022
USA	ZYNRELEF	44	90869615 06-AUG-2021	6782148 05-JUL-2022
Argentina	APONVI	5	4107676 18-MAR-2022	
Argentina	APONVI	42	4107677 18-MAR-2022	
Argentina	APONVI	44	4107678 18-MAR-2022	
Argentina	APONVIE	5	4107682 18-MAR-2022	
Argentina	APONVIE	42	4107684 18-MAR-2022	
Argentina	APONVIE	44	4107686 18-MAR-2022	
Argentina	CINVANTI	5	3757720 12-NOV-2018	3026050 27-SEP-2019
Argentina	CINVANTI – APREPITANT - INJECTABLE EMULSION 	5	3751517 19-OCT-2018	3246429 27-DEC-2021
Argentina	DALA	42	4000121 08-APR-2021	3350924 12-DEC-2022
Argentina	DALA	44	4000122 08-APR-2021	3350925 12-DEC-2022
Argentina	DEVELOPING BEST IN CLASS MEDICINES. IMPROVING LIVES.	5	3476169 04-FEB-2016	2885714 08-MAY-2017
Argentina	DEVELOPING BEST-IN-CLASS MEDICINE. IMPROVING LIVES.	42	3876321 26-FEB-2020	3173004 30-MAY-2021
Argentina	DEVELOPING BEST-IN-CLASS MEDICINE. IMPROVING LIVES.	44	3876322 26-FEB-2020	3242542 15-DEC-2021
Argentina	HERON CONNECT	35	3691219 13-MAR-2018	3008002 04-SEP-2019
Argentina	HERON CONNECT	36	3691221 13-MAR-2018	3108045 04-SEP-2020
Argentina	HERON THERAPEUTICS	42	3962303 27-NOV-2020	3287973 24-MAY-2022
Argentina	HERON THERAPEUTICS	44	3962305 27-NOV-2020	3287975 24-MAY-2022







Country of Registration	Mark	International Class(es)	Application No Filing Date	Registration No Registration Date
Argentina	HERON THERAPEUTICS 	42	3962298 27-NOV-2020	3287968 24-MAY-2022
Argentina	HERON THERAPEUTICS 	44	3962300 27-NOV-2020	3287970 24-MAY-2022
Argentina	SYNDURVA	5	3713488 01-JUN-2018	3011223 10-SEP-2019
Argentina	ZYNRELEF	5	3713487 01-JUN-2018	3011222 10-SEP-2019
Argentina	ZYNRELEF	10	4090277 20-JAN-2022	
Argentina	ZYNRELEF	42	4090279 20-JAN-2022	
Argentina	ZYNRELEF	44	4090280 20-JAN-2022	
Argentina	ZYNRELEF ZYNRELEF	5	3990154 09-MAR-2021	3317117 11-AUG-2022
Argentina	ZYNRELEF ZYNRELEF	42	3990155 09-MAR-2021	3317118 11-AUG-2022
Argentina	ZYNRELEF ZYNRELEF	44	3990156 09-MAR-2021	3317119 11-AUG-2022
Argentina	ZYNRELEF 	5	3990157 09-MAR-2021	3317120 11-AUG-2022
Argentina	ZYNRELEF 	10	4090276 20-JAN-2022	
Argentina	ZYNRELEF 	10	4090278 20-JAN-2022	
Argentina	ZYNRELEF 	42	3990158 09-MAR-2021	3317121 11-AUG-2022
Argentina	ZYNRELEF 	44	3990159 09-MAR-2021	3317122 11-AUG-2022
Brazil	CINVANTI	5	916267512 16-NOV-2018	916267512 20-AUG-2019





Country of Registration	Mark	International Class(es)	Application No Filing Date	Registration No Registration Date
Brazil	CINVANTI (APREPITANT) INJECTABLE EMULSION 	5	916103030 18-OCT-2018	916103030 20-AUG-2019
Brazil	DALA	5	918357616 01-OCT-2019	918357616 05-MAY-2020
Brazil	DALA - DUAL ACTING LOCAL ANESTHETIC	5	918357748 01-OCT-2019	918357748 05-MAY-2020
Brazil	HERON CONNECT	35	914322290 13-MAR-2018	914322290 02-APR-2019
Brazil	HERON CONNECT	36	914322354 13-MAR-2018	914322354 02-APR-2019
Brazil	HERON THERAPEUTICS	5	908121571 14-AUG-2014	908121571 17-JAN-2017
Brazil	HERON THERAPEUTICS 	5	908121636 14-AUG-2014	908121636 17-JAN-2017
Brazil	SYNDURVA	5	914809865 06-JUN-2018	914809865 14-MAY-2019
Brazil	ZYNRELEF	5	914809903 06-JUN-2018	914809903 14-MAY-2019
Canada	APONVI		2190869 16-MAR-2022	
Canada	APONVIE		2190870 16-MAR-2022	
Canada	APONVIE 		2255888 30-MAR-2023	
Canada	APONVIE 		2257288 30-MAR-2023	
Canada	BIOCHROMOMER		1111968 8-AUG-2001	TMA732278 13-JAN-2009
Canada	CINVANTI		1929278 7-NOV-2018	TMA1077608 28-APR-2020
Canada	CINVANTI (APREPITANT) INJECTABLE EMULSION & Design 		1925911 18-OCT-2018	TMA1093572 12-FEB-2021
Canada	DALA		2119276 7-APR-2021	
Canada	DEVELOPING BEST-IN-CLASS MEDICINE. IMPROVING LIVES.		1766380 4-FEB-2016	TMA1047856 8-AUG-2019
Canada	DEVELOPING BEST-IN-CLASS MEDICINE. IMPROVING LIVES.		2032301 26-FEB-2020	TMA1118631 26-JAN-2022









Country of Registration	Mark	International Class(es)	Application No Filing Date	Registration No Registration Date
Canada	HERON		2141758 3-SEP-2021	TMA1158436 28-DEC-2022
Canada	HERON CONNECT		1885525 28-FEB-2018	TMA1072726 14-FEB-2020
Canada	HERON THERAPEUTICS		1689356 13-AUG-2014	TMA1040397 11-JUL-2019
Canada	HERON THERAPEUTICS		2082014 9-NOV-2020	TMA1188261 5-JUL-2023
Canada	HERON THERAPEUTICS & Design 		1689357 13-AUG-2014	TMA1033018 27-JUN-2019
Canada	HERON THERAPEUTICS 		2082012 9-NOV-2020	
Canada	SUSTOL Design 		1766379 4-FEB-2016	TMA969650 2-MAY-2017
Canada	SYNDURVA		1901716 30-MAY-2018	TMA1082088 29-SEP-2020
Canada	ZYNRELEF		1901715 30-MAY-2018	TMA1077614 6-OCT-2020
Canada	ZYNRELEF		2170273 19-JAN-2022	
Canada	ZYNRELEF 		2103335 8-MAR-2021	
Canada	ZYNRELEF 		2168751 19-JAN-2022	
Canada	ZYNRELEF 		2101599 8-MAR-2021	
Canada	ZYNRELEF 		2168750 19-JAN-2022	
China	HERON THERAPEUTICS	5	49665132 11-SEP-2020	49665132 28-APR-2021
China	HERON THERAPEUTICS	42	49748535 15-SEP-2020	49748535 07-OCT-2021
China	HERON THERAPEUTICS	44	49748534 15-SEP-2020	49748534 28-MAY-2021
European Union	APONVIE APONVIE	5, 42, 44	18770652 04-OCT-2022	18770652 15-FEB-2023

Country of Registration	Mark	International Class(es)	Application No Filing Date	Registration No Registration Date
European Union	APONVIE 	5, 42, 44	18770657 04-OCT-2022	18770657 15-FEB-2023
European Union	BIOCHRONOMER	5, 10	2344919 08-AUG-2001	2344919 03-APR-2003
European Union	CINVANTI (APREPITANT) INJECTABLE EMULSION 	5	17968479 15-OCT-2018	17968479 27-FEB-2019
European Union	HERON	5	18416510 04-MAR-2021	18416510 30-JUN-2021
European Union	HERON THERAPEUTICS 	5	18418407 05-MAR-2021	18418407 30-JUN-2021
European Union	SUSTOL	5	8735656 04-DEC-2009	8735656 11-JUN-2010
European Union	SUSTOL 	5	14463913 13-AUG-2015	14463913 10-DEC-2015
European Union	SUSTOL CONNECT 	5	14698567 21-OCT-2015	14698567 22-FEB-2016
European Union	ZARMA	5	8735623 04-DEC-2009	8735623 11-JUN-2010
European Union	ZYNRELEF 	5, 42, 44	18306682 14-SEP-2020	18306682 04-FEB-2021
European Union	ZYNRELEF 	10	18641607 20-JAN-2022	18641607 02-JUN-2022
European Union	ZYNRELEF 	5, 42, 44	18305892 14-SEP-2020	18305892 05-FEB-2021
European Union	ZYNRELEF 	10	18641609 20-JAN-2022	18641609 02-JUN-2022
Hong Kong	APONVI	5, 42, 44	305910363 18-MAR-2022	305910363 18-MAR-2022
Hong Kong	APONVIE	5, 42, 44	305910354 18-MAR-2022	305910354 18-MAR-2022
Hong Kong	CINVANTI	5	304729861 09-NOV-2018	304729861 09-NOV-2018
Hong Kong	CINVANTI (aprepitant) injectable emulsion 	5	304701627 16-OCT-2018	304701627 16-OCT-2018







Country of Registration	Mark	International Class(es)	Application No Filing Date	Registration No Registration Date
Hong Kong	CINVANTI CONNECT	35, 36	304448854 05-MAR-2018	304448854 05-MAR-2018
Hong Kong	DALA	5	305073624 02-OCT-2019	305073624 02-OCT-2019
Hong Kong	DALA	42, 44	305587345 09-APR-2021	
Hong Kong	HERON	5	305733513 01-SEP-2021	305733513 01-SEP-2021
Hong Kong	HERON CONNECT	35, 36	304448863 05-MAR-2018	304448863 05-MAR-2018
Hong Kong	HERON THERAPEUTICS	5	303103406 15-AUG-2014	303103406 15-AUG-2014
Hong Kong	HERON THERAPEUTICS 	42, 44	305443579 11-NOV-2020	305443579 11-NOV-2020
Hong Kong	HERON THERAPEUTICS 	5	303103398 15-AUG-2014	303103398 15-AUG-2014
Hong Kong	HERON THERAPEUTICS 	42, 44	305443560 11-NOV-2020	305443560 11-NOV-2020
Hong Kong	HERON THERAPEUTICS DEVELOPING BEST-IN-CLASS MEDICINE. IMPROVING LIVES. Developing Best-In-Class Medicine. Improving Lives. A  B 	5	303683755 12-FEB-2016	303683755 12-FEB-2016
Hong Kong	SUSTOL	5	301491705 04-DEC-2009	301491705 04-DEC-2009
Hong Kong	Sustol 	5	303681162 05-FEB-2016	303681162 05-FEB-2016
Hong Kong	SYNDUVA	5	304549032 01-JUN-2018	304549032 01-JUN-2018
Hong Kong	ZYNRELEF	5	304549005 01-JUN-2018	304549005 01-JUN-2018
Hong Kong	ZYNRELEF	10, 42, 44	305864644 21-JAN-2022	305864644 21-JAN-2022
Hong Kong	ZYNRELEF 	5, 42, 44	305557159 10-MAR-2021	305557159 10-MAR-2021

Country of Registration	Mark	International Class(es)	Application No Filing Date	Registration No Registration Date
Hong Kong	ZYNRELEF 	10	305864824 21-JAN-2022	305864824 21-JAN-2022
Hong Kong	ZYNRELEF 	5, 42, 44	305557168 10-MAR-2021	305557168 10-MAR-2021
Hong Kong	ZYNRELEF 	10	305864833 21-JAN-2022	305864833 21-JAN-2022
India	APONVI	5, 42, 44	5487966 16-MAR-2022	
India	APONVIE	5, 42, 44	5498246 16-MAR-2022	
India	APONVIE	5, 42, 44	5942842 30-MAR-2023	
India	APONVIE	5, 42, 44	5927381 30-MAR-2023	
India	CINVANTI	5	4029895 06-NOV-2018	
India	CINVANTI (APREPITANT) INJECTABLE EMULSION 	5	4022260 12-OCT-2018	
India	CINVANTI CONNECT	35, 36	3982948 02-MAR-2018	
India	DALA	42, 44	5048483 07-APR-2021	
India	DALA - DUAL ACTING LOCAL ANESTHETIC	42, 44	4988730 07-APR-2021	
India	DEVELOPING BEST-IN-CLASS MEDICINE. IMPROVING LIVES.	5	3336064 09-FEB-2016	
India	HERON CONNECT	35, 36	3895731 02-MAR-2018	
India	HERON THERAPEUTICS	5	2910311 12-AUG-2014	
India	HERON THERAPEUTICS 	42, 44	4850399 09-NOV-2020	
India	HERON THERAPEUTICS	42, 44	4856350 09-NOV-2020	
India	SUSTOL (WITH DEVICE) 	5	3330603 01-FEB-2016	
India	SYNDURVA	5	3915193 25-MAY-2018	

Country of Registration	Mark	International Class(es)	Application No Filing Date	Registration No Registration Date
India	ZYNRELEF	5	3910775 25-MAY-2018	
India	ZYNRELEF	10, 42, 44	5357209 19-JAN-2022	
India	ZYNRELEF ZYNRELEF	5, 42, 44	4963011 08-MAR-2021	
India	ZYNRELEF ZYNRELEF	10	5353523 19-JAN-2022	
India	ZYNRELEF 	5, 42, 44	4959273 08-MAR-2021	
India	ZYNRELEF 	10	5353619 19-JAN-2022	
International Register	APONVI	5, 42, 44		1664925 16-MAR-2022
International Register	APONVIE 	5, 42, 44		1728910 30-MAR-2023
International Register	APONVIE	5, 42, 44		1665040 16-MAR-2022
International Register	APONVIE	5, 42, 44		1727494 30-MAR-2023
International Register	CINVANTI	5		1438814 06-NOV-2018
International Register	CINVANTI (aprepitant) injectable emulsion 	5		1438340 12-OCT-2018
International Register	CINVANTI CONNECT	35, 36		1428129 02-MAR-2018
International Register	DALA	42, 44		1600383 07-APR-2021
International Register	DEVELOPING BEST-IN-CLASS MEDICINE. IMPROVING LIVES.	5		1294005 09-FEB-2016
International Register	DEVELOPING BEST-IN-CLASS MEDICINE. IMPROVING LIVES.	42, 44		1533690 26-FEB-2020
International Register	HERON	5		1619985 03-SEP-2021
International Register	HERON CONNECT	35, 36		1412816 02-MAR-2018
International Register	HERON THERAPEUTICS	5		1228757 12-AUG-2014
International Register	HERON THERAPEUTICS	42, 44		1573986 09-NOV-2020

Country of Registration	Mark	International Class(es)	Application No Filing Date	Registration No Registration Date
International Register	HERON THERAPEUTICS 	5		1228304 12-AUG-2014
International Register	HERON THERAPEUTICS 	42, 44		1574107 09-NOV-2020
International Register	SUSTOL	5		1023123 03-DEC-2009
International Register	Sustol 	5		1291496 01-FEB-2016
International Register	ZARMA	5		1253327 07-APR-2015
International Register	ZYNRELEF	5		1416175 25-MAY-2018
International Register	ZYNRELEF	10, 42, 44		1648558 19-JAN-2022
International Register	ZYNRELEF 	5, 42, 44		1588282 08-MAR-2021
International Register	ZYNRELEF 	10		1646409 19-JAN-2022
International Register	ZYNRELEF 	5, 42, 44		1587680 08-MAR-2021
International Register	 ZYNRELEF	10		1646412 19-JAN-2022
Israel	CINVANTI	5	311808 06-NOV-2018	
Israel	CINVANTI (aprepitant) injectable emulsion 	5	311656 12-OCT-2018	
Israel	DALA	5	322280 02-OCT-2019	
Israel	DALA - DUAL ACTING LOCAL ANESTHETIC	5	322761 02-OCT-2019	
Israel	HERON CONNECT	35, 36	307318 02-MAR-2018	
Israel	SYNDURVA	5	308029 25-MAY-2018	

Country of Registration	Mark	International Class(es)	Application No Filing Date	Registration No Registration Date
Israel	ZYNRELEF	5	307845 25-MAY-2018	
Japan	ZARMA	5	2014-069865 03-DEC-2009	5827060 19-FEB-2016
Mexico	GANITE	5	635995 19-DEC-2003	820315 30-JAN-2004
New Zealand	SUSTOL	5	816878 07-DEC-2009	816878 10-JUN-2010
New Zealand	ZARMA	5	816879 07-DEC-2009	816879 10-JUN-2010
Taiwan	APONVI	5, 42, 44	111017941 17-MAR-2022	02285138 01-MAR-2023
Taiwan	APONVIE	5, 42, 44	111017940 17-MAR-2022	02285137 01-MAR-2023
Taiwan	CINVANTI	5	107072324 08-NOV-2018	01983598 01-MAY-2019
Taiwan	CINVANTI APREPITANT INJECTABLE  EMULSION	5	107066450 15-OCT-2018	
Taiwan	CINVANTI CONNECT	35, 36	107013032 05-MAR-2018	
Taiwan	DALA	5	108064877 02-OCT-2019	02055733 01-MAY-2020
Taiwan	DALA	42, 44	110024179 08-APR-2021	02194856 01-JAN-2022
Taiwan	DALA DUAL ACTING LOCAL ANESTHETIC	5	108064876 02-OCT-2019	02058427 16-MAY-2020
Taiwan	DALA DUAL ACTING LOCAL ANESTHETIC	42, 44	110024178 08-APR-2021	
Taiwan	DEVELOPING BEST IN CLASS MEDICINES IMPROVING LIVES	5	105007340 04-FEB-2016	
Taiwan	HERON	5	110063322 01-SEP-2021	02220723 16-MAY-2022
Taiwan	HERON CONNECT	35, 36	107013033 05-MAR-2018	01956954 01-DEC-2018
Taiwan	HERON THERAPEUTICS	5	103047094 15-AUG-2014	01704321 01-MAY-2015
Taiwan	HERON THERAPEUTICS	42, 44	109079564 11-NOV-2020	02187910 01-DEC-2021
Taiwan	HERON THERAPEUTICS 	5	103047098 15-AUG-2014	01709228 01-JUN-2015
Taiwan	HERON THERAPEUTICS 	42, 44	109079563 11-NOV-2020	02184408 16-NOV-2021

Country of Registration	Mark	International Class(es)	Application No Filing Date	Registration No Registration Date
Taiwan	SUSTOL	5	098054676 08-DEC-2009	01421152 01-AUG-2010
Taiwan	SUSTOL 	5	105006727 03-FEB-2016	01790798 16-SEP-2016
Taiwan	SYNDURVA	5	107035037 04-JUN-2018	01954246 01-DEC-2018
Taiwan	ZARMA	5	098054677 08-DEC-2009	01421153 01-AUG-2010
Taiwan	ZYNRELEF	5	107035036 04-JUN-2018	01954245 01-DEC-2018
Taiwan	ZYNRELEF	10, 42, 44	111004737 20-JAN-2022	02267443 01-DEC-2022
Taiwan	ZYNRELEF 	5, 42, 44	110015638 09-MAR-2021	02184560 16-NOV-2021
Taiwan	ZYNRELEF 	10	111004739 20-JAN-2022	02265079 01-DEC-2022
Taiwan	ZYNRELEF ZYNRELEF	5, 42, 44	110015636 09-MAR-2021	02184559 16-NOV-2021
Taiwan	ZYNRELEF ZYNRELEF	10	111004738 20-JAN-2022	02265078 01-DEC-2022
United Kingdom	APONVIE APONVIE APONVIE APONVIE	5, 42, 44	3835633 04-OCT-2022	3835633 23-DEC-2022
United Kingdom	APONVIE APONVIE  APONVIE	5, 42, 44	3835657 04-OCT-2022	3835657 23-DEC-2022
United Kingdom	BIOCHRONOMER	5, 10	UK00902344919 08-AUG-2001	UK00902344919 03- APR-2003
United Kingdom	CINVANTI	5	UK00801438814 06-NOV-2018	UK00801438814 20- MAY-2019
United Kingdom	CINVANTI (APREPITANT) INJECTABLE EMULSION 	5	UK00917968479 15-OCT-2018	UK00917968479 27- FEB-2019
United Kingdom	CINVANTI CONNECT	35, 36	UK00801428129 02-MAR-2018	UK00801428129 19- MAR-2019
United Kingdom	DALA	5	UK00801497655 02-OCT-2019	UK00801497655 19- JUN-2020
United Kingdom	HERON CONNECT	35, 36	UK00801412816 02-MAR-2018	UK00801412816 21- DEC-2018
United Kingdom	HERON THERAPEUTICS	5	UK00801228757 12-AUG-2014	UK00801228757 03- NOV-2015
United Kingdom	HERON THERAPEUTICS 	5	UK00801228304 12-AUG-2014	UK00801228304 20- OCT-2015








Country of Registration	Mark	International Class(es)	Application No Filing Date	Registration No Registration Date
United Kingdom	HERON THERAPEUTICS 	5	3688589 01-SEP-2021	3688589 10-DEC-2021
United Kingdom	SUSTOL	5	UK00908735656 04-DEC-2009	UK00908735656 11- JUN-2010
United Kingdom	SUSTOL 	5	UK00914463913 13-AUG-2015	UK00914463913 10- DEC-2015
United Kingdom	SUSTOL CONNECT 	5	UK00914698567 21-OCT-2015	UK00914698567 22- FEB-2016
United Kingdom	SYNDURVA	5	UK00801416972 25-MAY-2018	UK00801416972 11- JAN-2019
United Kingdom	ZARMA	5	UK00908735623 04-DEC-2009	UK00908735623 11- JUN-2010
United Kingdom	ZYNRELEF	5	UK00801416175 25-MAY-2018	UK00801416175 08- JAN-2019
United Kingdom	ZYNRELEF 	5, 42, 44	3606857 09-MAR-2021	3606857 23-JUL-2021
United Kingdom	ZYNRELEF 	10	3745260 20-JAN-2022	3745260 15-APR-2022
United Kingdom	ZYNRELEF 	5, 42, 44	3606875 09-MAR-2021	3606875 23-JUL-2021
United Kingdom	ZYNRELEF 	10	3745254 20-JAN-2022	3745254 15-APR-2022

EXHIBIT D

Mask Works

None.